
The scheme, announced in August 2023, is aimed at fostering innovation in the pharmaceutical and medical devices sectors, with a total financial…
Government clarifies re-labelling of medicines is not mandatory as new GST rates take effect from September 22.
Zydus Lifesciences has launched VaxiFlu, India’s first trivalent influenza vaccine for seasonal flu protection. The vaccine follows WHO’s 2025–26 guidelines…
Allowing data exclusivity would prevent the drug regulator — Central Drugs Standard Control Organisation — from granting marketing approval for…
Investors are increasingly turning to ‘safer’ MNC pharma stocks with a domestic focus at a time when the Trump administration…
Nomura’s June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Zydus posting strong specialty…
Elara Capital observes that Aurobindo Pharma has 14 biosimilars in the pipeline. The company has also filed 3 biosimilars for…
Sun Pharma slides 6% after weak Q1 FY26 results, but Motilal Oswal still recommends Buy—discover the three reasons to consider…
Dr Gaurav Kharya of Indraprastha Apollo Hospitals explains how stem cell therapies could potentially cure severe Type 1 diabetes. Explore…
Once the regulator’s guidance is accepted by the European Commission, the authorisation is valid in all 27 EU member countries…
AbbVie has entered into a $700 million licensing agreement with IGI Therapeutics to co-develop ISB 2001, a promising trispecific T-cell…
Nectar Lifesciences’ API and formulation business generated 98.33 percent of the company’s total revenue/ income in the fiscal year 2025.…
Worries about further hiccups in the potential trade deal and consequent higher tariffs between India and the United States are…
US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro pen, its widely used diabetes and weight-loss…
Cipla aims for FY26 growth via inorganic expansion and new product launches, especially 2-3 peptide assets. Its FY25 report highlights…
Glenmark said that the FDA has issued a Form 483 upon the conclusion of its inspection at the manufacturing facility.…
The presence of multinational pharma companies (MNCs) in India’s drug market continues to shrink, reaching 14.5% in May 2025 from…
What do these Warren Buffetts of India like Mukul Agarwal, Vijay Kedia, Ashish Kacholia and Vanaja Iyer have in common,…